insurance

First Opinion By Robin Feldman

Make list price the touchstone for drug pricing across the supply chain

Politics By Lev Facher

Trump administration finalizes rule forcing insurers to disclose negotiated prices, including for drugs

First Opinion By Rebecca Kolins Givan

President Trump is benefiting from single-payer, single-provider health care. We all should

First Opinion By Andrew Parece and Matthew Majewski

Instead of eliminating drug rebates, use average sales price to set co-insurance levels

Special Report By Erin Brodwin and Casey Ross

Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO

Business By Casey Ross

Gawande says leaving Haven CEO job will allow him to focus on Covid-19

Business By Casey Ross and Erin Brodwin

Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?

First Opinion By Eric Schneider

Super Tuesday results suggest that Americans ‘aren’t looking for big structural changes’ in health care

Pharmalot By Ed Silverman

Americans with employer coverage saw growth in drug spending outpace other medical costs

First Opinion By Dorothy Pomerantz

I was fortunate to get post-23andMe genetic counseling. Everyone should have that option

First Opinion By Laura Hawks and Danny McCormick

The ACA gave more Americans insurance, but not the health care they need

First Opinion By Christopher T. Robertson

Does ‘no more copays, no more deductibles’ really represent radical health care reform?

Pharmalot By Ed Silverman

Lilly exec says ‘there are no villains’ in the high-priced insulin market

First Opinion By Robin Gelburd

Using states as living laboratories to solve surprise medical billing

First Opinion By Allyson Y. Schwartz

Deadline looms to stop the Health Insurance Tax — but Congress has been there before

Off the Charts By Jennifer Adaeze Okwerekwu

My baby needed expensive intensive care, but my insurer was taking a long weekend. How can this be?

First Opinion By Patrick J. Kennedy

Mental health and addiction care are poorly covered by insurance networks

Pharmalot By Ed Silverman

Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work

Politics By Lev Facher

A new bill would let more doctors prescribe addiction treatments without waiting for insurers’ permission

First Opinion By Shea McCarthy

Working with ICER, or around it, on cost-effectiveness estimates

First Opinion By Jeremy Schafer

Should employers take a chance on little-known Embarc to pay for gene therapy?

First Opinion By Eli Cahan

The emergence of laboratory benefits managers: PBM déjà vu?

First Opinion By David Boettiger

The health system in my native Australia has a lot to learn from the U.S.

First Opinion By Shawn Morris

Medicare’s Shared Savings Program results should have made headlines. It got a ‘collective shrug’ instead

First Opinion By Nav Persaud and Danielle Martin

It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion